Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Mobile Surgical Vehicle Echocardiography-guided ASD closure Group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
ASD - Atrial Septal Defect
1 trial -
PCIA group
The First People's Hospital of Lianyungang
Postoperative Pain
1 trial -
TACHOSIL GROUP
Takeda
Lymphocele
1 trial -
Topiramate
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Alcohol Dependence
1 trial -
Treatment group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Triple combination therapy group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Type 2 Diabetes Mellitus
1 trial -
a control group
The First People's Hospital of Lianyungang
Disorder of Stomach Function and Feeding Problems in Newborn
1 trial -
lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group
Chinese University of Hong Kong
Shock, Septic
1 trial -
rhGM-CSF group
The First People's Hospital of Lianyungang
Mycoses
1 trial -
rhGM-CSF group
Biotech Pharmaceutical Co.,
Mycoses
1 trial -
risperidone
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Neuroleptic-Induced Tardive Dyskinesia
1 trial -
ASC09/ritonavir group
The First People's Hospital of Lianyungang
2019-nCoV
1 trial -
Aescin in Horse Chestnut
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Anorectal Disorder
1 trial -
Bundle Group 1 with Nutrilite Lifestyle
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Osteoarthritis
1 trial -
Combination group
Hospital Authority, Hong Kong
Cardiac Arrest
1 trial -
Dapagliflozin Treatment Group
The First People's Hospital of Lianyungang
Atrial Fibrillation (AF)
1 trial -
Dexmedetomidine group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colonoscopy
1 trial -
Efgartigimod + Telitacicept (1-week interval) group
The First People's Hospital of Lianyungang
Myasthenia Gravis
1 trial -
Esketamine-lidocaine group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Postoperative Chronic Pain
1 trial -
Experimental group
The First People's Hospital of Lianyungang
Overweight or Obesity
1 trial -
GD007 Low-dose drug group
The First People's Hospital of Lianyungang
Moderate-Severe Intrauterine Adhesions
1 trial -
Group A
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Crohn Disease
1 trial -
Group A (clinical guideline+machine learning)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Group S: sugammadex injection
Hospital Authority, Hong Kong
Head and Neck Surgery
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources